Dexcom

Health Care Health Care Equipment San Diego, California Last filing Feb 12, 2026 · FY2025

                    Revenue
                    FY2025
                
$4.7B
                    3y CAGR +17.0%
                    
                    P95
                    
                    +15.6%
                    
                    Net income
                    FY2025
                
$836.3M
                    Net margin +17.9%
                    
                    P73
                    
                    +45.1%
                    
                    Total assets
                    FY2025
                
$6.3B
                    ROA +13.2%
                    
                    P82
                    
                    -2.2%
                    
                    Operating cash flow
                    FY2025
                
$1.4B
                    FCF margin +23.1%
                    
                    P84
                    
                    +45.6%

17 yrs · FY2009–FY2025 9 filed · 0 derived · 0 blank

1Y 3Y 5Y 10Y

Dollars % of revenue % of assets YoY % CAGR

Each cell as a share of that year’s total assets.

Balance Sheet

Assets, liabilities, and equity

32 accounts · 5 years

Total assets $6.3B

Total liabilities $3.6B

Shareholders equity $2.7B

Account	2025	2024	2023	2022	2021
Assets
Cash and Cash Equivalents	14.5%	9.3%	9.0%	11.9%	21.6%
Short Term Investments	3.4%	26.7%	34.5%	33.6%	28.0%
Accounts Receivable	19.2%	15.5%	15.5%	13.2%	10.6%
Inventory	9.9%	8.4%	8.9%	5.7%	7.3%
Prepaid Expenses	3.0%	2.7%	2.7%	3.6%	1.7%
Other Current Assets	0.5%	0.6%	0.8%	0.7%	—
Total Current Assets	63.6%	66.3%	70.7%	68.0%	75.8%
Property,Plant and Equipment	24.6%	20.7%	17.8%	19.6%	16.5%
Operating Lease Assets	1.2%	1.0%	1.1%	1.5%	1.8%
Goodwill	0.4%	0.4%	0.4%	0.5%	0.5%
Intangible Assets	1.1%	1.6%	2.1%	3.2%	0.0%
Long Term Investments	3.4%	1.8%	0.6%	0.4%	—
Deferred Tax Assets	4.7%	7.4%	6.7%	6.3%	4.5%
Other Noncurrent Assets	4.4%	2.7%	1.2%	0.9%	0.9%
Total Assets	100.0%	100.0%	100.0%	100.0%	100.0%
Liabilities
Accounts Payable	5.4%	5.3%	4.4%	4.4%	4.0%
Accrued Liabilities	0.7%	0.6%	0.6%	0.9%	1.0%
Operating Lease Liabilities	0.3%	0.3%	0.3%	0.4%	0.4%
Other Current Liabilities	0.1%	—	—	—	—
Total Current Liabilities	33.8%	45.2%	24.8%	34.1%	14.8%
Long Term Debt	0.0%	0.0%	0.0%	0.0%	0.0%
Operating Lease Liabilities Noncurrent	1.2%	1.0%	1.3%	1.8%	2.0%
Other Noncurrent Liabilities	2.2%	2.3%	2.0%	2.4%	1.9%
Total Liabilities	56.7%	67.6%	67.0%	60.5%	53.7%
Equity
Preferred Stock	0.0%	0.0%	0.0%	0.0%	0.0%
Common Stock	0.0%	0.0%	0.0%	0.0%	0.0%
Additional Paid In Capital	36.0%	32.3%	56.1%	41.9%	51.5%
Retained Earnings	38.4%	24.6%	16.3%	8.9%	-1.0%
Treasury Stock	32.9%	24.4%	39.1%	11.0%	4.2%
Accumulated Other Comprehensive Income	1.8%	-0.1%	-0.3%	-0.2%	0.0%
Total Stockholders Equity	43.3%	32.4%	33.0%	39.5%	42.0%
Total Liabilitiesand Equity	100.0%	100.0%	100.0%	100.0%	100.0%

Income Statement

Revenue, expense, and profitability

19 accounts · 5 years

Revenue $4.7B

Operating income $911.8M

Net income $836.3M

Account	2025	2024	2023	2022	2021
IncomeStatement
Revenues Total Revenue	73.5%	62.2%	57.8%	54.0%	50.3%
Expenses Cost of Revenue	29.3%	24.6%	21.3%	19.0%	15.8%
Expenses Research and Development	9.4%	8.5%	8.1%	9.0%	10.6%
Expenses Selling,General and Administrative	20.4%	19.8%	18.9%	18.7%	16.7%
Expenses Depreciation and Amortization	4.0%	3.4%	3.0%	2.9%	2.1%
Expenses Share Based Compensation	2.5%	2.6%	2.4%	2.3%	2.3%
Expenses Operating Expenses	29.8%	28.3%	27.0%	27.7%	29.1%
Other Income Expense Gross Profit	44.2%	37.6%	36.5%	34.9%	34.6%
Other Income Expense Operating Income	14.4%	9.3%	9.5%	7.3%	5.5%
Other Income Expense Interest Expense	0.3%	0.3%	0.3%	0.3%	0.4%
Other Income Expense Other Income/expense	2.8%	1.7%	1.8%	-0.0%	-0.2%
Other Income Expense Income Before Tax	17.2%	10.9%	11.3%	7.2%	5.3%
Income Tax Income Tax Expense	4.0%	2.0%	2.7%	0.9%	0.8%
net Income net Income	13.2%	8.9%	8.6%	6.3%	4.5%
net Income Comprehensive Income	15.1%	9.0%	8.6%	6.1%	4.4%
Earnings Per Share Basic Eps	0.0%	0.0%	0.0%	0.0%	0.0%
Earnings Per Share Diluted Eps	0.0%	0.0%	0.0%	0.0%	0.0%
Earnings Per Share Weighted Average Shares Basic	6.2%	6.1%	6.2%	7.2%	8.0%
Earnings Per Share Weighted Average Shares Diluted	6.4%	6.4%	6.8%	7.9%	8.8%

Cash Flow Statement

Operating, investing, and financing flows

19 accounts · 5 years

Operating cash flow $1.4B

Investing cash flow $536.0M

Financing cash flow $-1.7B

Account	2025	2024	2023	2022	2021
CashFlow
Operating Activities net Income	13.2%	8.9%	8.6%	6.3%	4.5%
Operating Activities Depreciation and Amortization	0.6%	0.6%	0.7%	0.9%	2.0%
Operating Activities Stock Based Compensation	2.5%	2.6%	2.4%	2.3%	2.3%
Operating Activities Deferred Income Taxes	2.9%	-0.7%	-0.9%	-0.4%	0.3%
Operating Activities Changes In Operating Assets and Liabilities	4.4%	0.4%	7.9%	5.2%	4.3%
Operating Activities net Cash From Operating Activities	22.7%	15.3%	11.9%	12.4%	9.1%
Investing Activities Capital Expenditures	5.7%	5.5%	3.8%	6.8%	8.0%
Investing Activities Purchases of Investments	19.7%	39.7%	51.1%	42.0%	50.8%
Investing Activities Proceeds From Sale of Investments	34.1%	43.6%	47.0%	39.5%	54.8%
Investing Activities Other Investing Activities	-0.0%	0.2%	-0.0%	-0.0%	-0.2%
Investing Activities net Cash From Investing Activities	8.5%	-3.2%	-8.1%	-9.7%	-4.4%
Financing Activities Repurchase of Common Stock	7.9%	11.6%	11.0%	10.3%	0.0%
Financing Activities Proceeds From Stock Issuance	0.4%	0.4%	0.4%	0.4%	0.4%
Financing Activities Other Financing Activities	-0.1%	-0.2%	0.0%	-0.3%	-0.2%
Financing Activities net Cash From Financing Activities	-26.6%	-11.3%	-5.1%	-10.2%	0.2%
Cash Reconciliation Effect of Exchange Rate On Cash	0.3%	-0.1%	0.0%	-0.1%	-0.0%
Cash Reconciliation net Change In Cash	4.9%	0.6%	-1.2%	-7.6%	4.8%
Cash Reconciliation Cash At Beginning of Period	14.5%	9.4%	9.1%	11.9%	21.7%
Cash Reconciliation Cash At End of Period	14.5%	9.4%	9.1%	11.9%	21.7%

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 5 years

Ratio	2025	2024	2023	2022	2021
Profitability
Gross margin	+60.1%	+60.5%	+63.2%	+64.7%	+68.6%
Operating margin	+19.6%	+14.9%	+16.5%	+13.4%	+10.9%
Net margin	+17.9%	+14.3%	+14.9%	+11.7%	+8.9%
FCF margin	+23.1%	+15.6%	+14.1%	+10.5%	+2.2%
Growth
Revenue CAGR (3y)	+17.0%	+18.1%	+23.4%	+25.4%	+33.4%
Returns
ROE	+30.5%	+27.4%	+26.2%	+16.0%	+10.6%
ROA	+13.2%	+8.9%	+8.6%	+6.3%	+4.5%
ROIC	+38.3%	+32.6%	+30.3%	+22.9%	+22.7%
Liquidity
Current ratio	1.88x	1.47x	2.84x	1.99x	5.11x
Quick ratio	1.00x	0.55x	0.99x	0.74x	2.17x
Leverage
D/E	1.31x	2.08x	2.03x	1.53x	1.28x
Interest coverage	49.83x	31.58x	29.44x	21.03x	14.14x
Efficiency
Asset turnover	0.74x	0.62x	0.58x	0.54x	0.50x
Cash conversion cycle	+151d	+136d	+176d	+114d	+153d

Valuation

Price against fundamentals

FY2025 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched

Dexcom

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Recent price history